Benzoquinone ansamycins
AssigneeKosan Biosciences, Inc.
InventorsDaniel Santi, David C. Myles, Zong-Qiang Tian, C. Richard Hutchinson, Robert Johnson, Yi-Qing Zhou, Li Feng
Life of this patent
Estimating the term…
Abstract
The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.
Claims6
A method for treatment of breast cancer or lung cancer in a subject suffering therefrom, comprising the steps of:
- (a) administering to said subject a substantially sub-toxic dose of an Hsp90 client protein inhibitor, wherein the Hsp90 client protein inhibitor is N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl(propoxy]-4-quinazolinamine (Iressa);
- (b) waiting a period of time sufficient to allow development of a substantially efficacious response;
- and
- (c) administering to said subject a synergistic dose of a benzoquinone ansamycin, wherein the benzoquinone ansamycin is 17-allylamino-17-desmethoxy-geldanamycin (17-AAG) or 17-(2-dimethylamino)ethylamino-17-desmethoxygeldanamycin (17-DMAG).
A method for treatment of breast cancer or lung cancer in a subject suffering therefrom, comprising the steps of:
- (a) administering to said subject a synergistic dose of a benzoquinone ansamycin, wherein the benzoquinone ansamycin is 17-allylamino-17-desmethoxy-geldanamycin (17-AAG) or 17-(2-dimethylamino)ethylamino-17-desmethoxygeldanamycin (17-DMAG);
- (b) waiting a period of time sufficient to allow development of a substantially efficacious response;
- and
- (c) administering to said subject a sub-toxic dose of an Hsp90 client protein inhibitor, wherein the Hsp90 client protein inhibitor is paclitaxel.
Dependencies are inferred from the claim text.